Maraviroc 150 mg QD plus lopinavir/ritonavir, a NRTI‐sparing regimen for HIV‐infected naïve patients: 48‐weeks final results

Silvia Nozza(IRCCS Ospedale San Raffaele), Adriano Lazzarin(Vita-Salute San Raffaele University), Davide De Battista(Vita-Salute San Raffaele University), Mauro Malnati(Vita-Salute San Raffaele University), Laura Galli(Vita-Salute San Raffaele University), Chiara Tommasi(University of Parma), Giuseppe Tambussi(San Raffaele University of Rome), Sonja Chiappetta(Sana Klinikum Offenbach), Massimo Di Pietro(Ospedale SS. Annunziata), Andrea Antinori(Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani)
Journal of the International AIDS Society
November 1, 2012
10.7448/ias.15.6.18232
Cited by 9

Related Papers

Monkeypox Virus Infection in Humans across 16 Countries — April–June 2022
|New England Journal of Medicine|2022|2.2k
Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study
|The Lancet|2019|1k
Efficacy of Enfuvirtide in Patients Infected with Drug-Resistant HIV-1 in Europe and Australia
|New England Journal of Medicine|2003|653
In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression
|Nature Medicine|1997|635
Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial
|The Lancet|2009|620